2022, Chronic pain management and Pharmaceuticals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2022

Chronic pain management

Pharmaceuticals

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

Digital Health Global

JANUARY 29, 2024

As showcased in the ‘ VIRPI ‘ study, ODD-403 marks a statistically significant advancement in chronic pain management. About Orion Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. The core therapy areas of our pharmaceutical R&D are oncology and pain.

Pharmaceuticals

Pharmaceuticals Chronic pain management Digital Health Pain management

Average Multiples and Key Drivers of Digital Therapeutics (DTx) M&A deals in 2023

Lloyd Price

NOVEMBER 25, 2023

These multiples are down from the levels seen in 2022, but they are still higher than the average EV to sales multiple for all industries. Here are some additional insights into DTx M&A deals in 2023: The most active acquirers in the DTx M&A market are pharmaceutical companies, followed by technology companies.

Pharmaceuticals

Pharmaceuticals Pain management Chronic pain management Mental health

Connected Health Pulse

Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain

Average Multiples and Key Drivers of Digital Therapeutics (DTx) M&A deals in 2023

Stay Connected